6:18 PM
 | 
Jan 29, 2014
 |  BC Extra  |  Clinical News

Medivation jumps on PREVAIL data

Medivation Inc. (NASDAQ:MDVN) jumped $8.51 (11%) to $84.29 on Wednesday after the company and partner Astellas Pharma Inc. (Tokyo:4503) reported final data from the Phase III PREVAIL trial evaluating Xtandi enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC). Once-daily oral Xtandi plus standard...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >